Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Oriol Solà"'
Autor:
Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Michael Berntgen, Mira Pavlovic, Peter Mol, Jürgen Wasem, Walter Van Dyck, Antonella Cardone, Christian Dierks, Anja Schiel, Renato Bernardini, Oriol Solà-Morales, Jörg Ruof, Wim Goettsch
Publikováno v:
Health Research Policy and Systems, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background The European Regulation on Health Technology Assessment (EU HTA R), effective since January 2022, aims to harmonize and improve the efficiency of common HTA across Member States (MS), with a phased implementation from January 2025
Externí odkaz:
https://doaj.org/article/660c1c179a5f4b32bace34cbb01905ab
Autor:
Elaine Julian, Oriol Solà-Morales, Maria João Garcia, Francine Brinkhuis, Mira Pavlovic, Carlos Martín-Saborido, Robin Doeswijk, Rosa Giuliani, Anne Willemsen, Wim Goettsch, Bernhard Wörmann, Urania Dafni, Heiner C. Bucher, Begoña Pérez-Valderrama, Renato Bernardini, Fabrizio Gianfrate, Carin A. Uyl-de Groot, Jörg Ruof
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 3, Pp 128-143 (2024)
Background: This work aimed to determine the role and action points for the involvement of medical societies in the European Health Technology Assessment (EU HTA) Methods: An online pre-convention survey was developed addressing four areas related to
Externí odkaz:
https://doaj.org/article/f7baa0ed8a53416196beab87cb2d5619
Autor:
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 1, Pp 21-34 (2024)
Objectives: Stakeholder involvement has long been considered a success factor for a joint European health technology assessment (HTA) process, and its relevance is now anchored in the EU HTA Regulation’s (EU HTAR) legislative wording. Therefore, we
Externí odkaz:
https://doaj.org/article/7f514bab01674db19ecb4093613aaea7
Autor:
Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, Walter Van Dyck, Steven Simoens, Isabelle Huys, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G.M. Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Elaine Julian
Publikováno v:
Journal of Market Access & Health Policy, Vol 11, Iss 1 (2023)
ABSTRACTInvolvement of all relevant stakeholders will be of utmost importance for the success of the developing EU HTA harmonization process.A multi-step procedure was applied to develop a survey across stakeholders/collaborators within the EU HTA fr
Externí odkaz:
https://doaj.org/article/b464df9353d045aaaaa896a7a0f4680a
Efficacy, Safety, and Evaluation Criteria of mHealth Interventions for Depression: Systematic Review
Autor:
Andrea Duarte-Díaz, Lilisbeth Perestelo-Pérez, Estel Gelabert, Noemí Robles, Antoni Pérez-Navarro, Josep Vidal-Alaball, Oriol Solà-Morales, Ariadna Sales Masnou, Carme Carrion
Publikováno v:
JMIR Mental Health, Vol 10, p e46877 (2023)
BackgroundDepression is a significant public health issue that can lead to considerable disability and reduced quality of life. With the rise of technology, mobile health (mHealth) interventions, particularly smartphone apps, are emerging as a promis
Externí odkaz:
https://doaj.org/article/d63a60c8d36e422b9cae41ad65ab9640
Publikováno v:
Breast, Vol 61, Iss , Pp 118-122 (2022)
Among stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barrie
Externí odkaz:
https://doaj.org/article/ee2e08f6a1344034bc519744dd38c139
Publikováno v:
Saudi Pharmaceutical Journal, Vol 29, Iss 9, Pp 946-954 (2021)
Objectives: Capacity building exercises are important to increase understanding of healthcare processes by key stakeholders, and to facilitate open discussions to build consensus. This study explored the views of a multi-stakeholder group of local Sa
Externí odkaz:
https://doaj.org/article/11a5160cd97c486f9070e5de6ec29332
Autor:
Oriol Solà-Morales
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Incentives for the development of Orphan Medicinal Products (OMP) development have been introduced in both the European Union and the US, yet there has been a relatively little investigation of the success of these policies. An in-depth analysis of t
Externí odkaz:
https://doaj.org/article/3ea7de4e17574c279a4b626a9ee7c26b
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies
Externí odkaz:
https://doaj.org/article/a238c42d5c034a8cb39c68d8ea07df43
Autor:
Paola Minghetti, Elena P. Lanati, Josie Godfrey, Oriol Solà-Morales, Olivier Wong, Sonia Selletti
Publikováno v:
Medicine Access @ Point of Care, Vol 1 (2017)
Introduction Almost 8,000 rare diseases exist worldwide, affecting approximately 350 million people. Nevertheless, only 5% receive a specific authorized or licensed treatment. The need for effective and rapidly available therapies is still unmet for
Externí odkaz:
https://doaj.org/article/c047b58bea7f4217b3d7835ed55e2694